Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months

Tsuf Eyran, Anna Vaisman-Mentesh, David Taussig, Yael Dror, Ligal Aizik, Aya Kigel, Shai Rosenstein, Yael Bahar, Dor Ini, Ran Tur-Kaspa, Tatyana Kournos, Dana Marcoviciu, Dror Dicker and Yariv Wine

PLOS Pathogens, 2022, vol. 18, issue 6, 1-20

Abstract: We describe the longitudinal kinetics of the serological response in COVID-19 recovered patients over a period of 14 months. The antibody kinetics in a cohort of 192 recovered patients, including 66 patients for whom follow-up serum samples were obtained at two to four clinic visits, revealed that RBD-specific antibodies decayed over the 14 months following the onset of symptoms. The decay rate was associated with the robustness of the response in that antibody levels that were initially highly elevated after the onset of symptoms subsequently decayed more rapidly. An exploration of the differences in the longitudinal kinetics between recovered patients and naïve vaccinees who had received two doses of the BNT162b2 vaccine showed a significantly faster decay in the naïve vaccinees, indicating that serological memory following natural infection is more robust than that following to vaccination. Our data highlighting the differences between serological memory induced by natural infection vs. vaccination contributed to the decision-making process in Israel regarding the necessity for a third vaccination dose.Author summary: The fundamental idea guiding vaccine science is that an ideal vaccine should induce immunity similar to the immunity produced by natural infection. A vaccine is designed to “train” the immune system in a way that it will mimic the stimulation necessary for immune development, yet not produce active disease. Understanding the persistence of antibodies in patients following recovery from natural infection with SARS-CoV-2 will help to highlight the differences between the breadth of the antibody responses following natural infection and vaccination and may inform us whether the vaccine “training” will effectively stimulate the immune system to provide long-lasting immunity. Using samples collected from recovered COVID-19 patients over an extended period of 14 months, we followed the persistence of antibodies and found an association between the antibody levels in proximity to recovery and the rate of decay. In addition, we found that the decay rate of antibodies in BNT162b2 vaccinees was significantly faster than that in recovered patients, suggesting that there are fundamental differences between the mechanisms of activation of the adaptive arm of the immune response following vaccine and natural infection. While natural infection involves full systemic activation, this activation may be incomplete with an mRNA vaccination, thereby affecting the capacity of the immune system to maintain an antibody reservoir over time.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1010569 (text/html)
https://journals.plos.org/plospathogens/article/fi ... 10569&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:ppat00:1010569

DOI: 10.1371/journal.ppat.1010569

Access Statistics for this article

More articles in PLOS Pathogens from Public Library of Science
Bibliographic data for series maintained by plospathogens ().